|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
Hester Biosciences net profit up 459%
|
|
Tuesday, 04 August, 2026, 12 : 00 PM [IST]
|
|
Our Bureau, Mumbai
|
Hester Biosciences Ltd has reported consolidated net profit of Rs 96.73 crore for the quarter ended June 2026, rise of 459 per cent Y-o-Y as compared to the net profit of Rs 17.30 crore reported in the Q1 FY26. Consolidated profitability during the quarter includes an exceptional gain of Rs 85.35 crore arising from the amendment of the Gates Foundation loan at Hester Africa.
EBITDA for Q1FY27 was reported at Rs 111.81 crore (EBITDA margin 145 per cent), 105.65 per cent rise Y-o-Y as compared to EBITDA of Rs 26.18 crore (EBITDA Margin 31 per cent) in Q1FY26. Revenue from operations of the company for the Q1FY27 was reported at Rs 77.24 crore as compared to the revenue from operations of Rs 84.11 crore in Q1FY26.
Consolidated profitability during the quarter includes an exceptional gain arising from the amendment of the Gates Foundation loan at Hester Africa. During the quarter, the outstanding loan was reduced from $12.0 million to $ 5.0 million, accrued interest was waived and the revised loan was made interest-free, resulting in an exceptional accounting gain of Rs 85.35 crore.
Consolidated revenues were lower compared to the corresponding quarter of the previous year primarily due to lower revenues from the Nepal and Africa operations - Nepal continued to experience variability in institutional order timing and local market conditions. Africa business remained focused on strengthening registrations, expanding market development activities and building long-term commercial opportunities across the continent.
The company remains committed to its long-term strategy of Building with Intent. Growing with Science. While certain parts of the business continue to be influenced by the timing of government immunisation programmes and international market conditions, the company remains focused on building long-term competitive advantages through scientific innovation, manufacturing capability and disciplined execution. Hester believes the investments made over the past few years position the company well to deliver sustainable growth and create long-term value for all stakeholders.
During FY27, the company will continue to focus on: Strengthening its biologicals portfolio across Poultry and Animal Healthcare; Expanding market penetration across domestic and export markets; Advancing Research and Development through continued investments in new products and regulatory submissions; Improving manufacturing efficiency and enhancing utilisation of recently commissioned facilities; Continuing to strengthen operational excellence, cost discipline and execution capabilities across the organisation.
|
|
|
|
|
|
|
|
|
|